| Safety and feasibility of collateral blood flow augmentation after intravenous thrombolysis. | |
| | |
MedLine Citation:
|
PMID: 21350210 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND PURPOSE: Collateral flow augmentation using partial aortic occlusion may improve cerebral perfusion in acute stroke. We assessed the safety and feasibility of partial aortic occlusion immediately after intravenous tissue plasminogen activator. METHODS: We conducted an open-label pilot study of partial aortic occlusion after thrombolysis. The primary end point was all serious adverse events within 30 days of treatment. RESULTS: None of the 22 patients enrolled developed symptomatic parenchymal hemorrhages. Asymptomatic hemorrhagic transformation occurred in 9 patients. Procedure-related adverse events were limited to groin complications (n=13). Seventy-seven percent of patients experienced neurological improvement (≥4-point improvement of the National Institutes of Health Stroke Scale score). CONCLUSIONS: Partial aortic occlusion as an adjunct to thrombolysis in the treatment of acute stroke appears safe. Studies aimed at determining the efficacy of this therapeutic approach are warranted. CLINICAL TRIAL REGISTRATION INFORMATION: URL: http://www.clinicaltrials.gov. Unique Identifier: NCT01006993. |
| | |
Authors:
|
Derek J Emery; Peter D Schellinger; Daniel Selchen; Andre G Douen; Richard Chan; Ashfaq Shuaib; Kenneth S Butcher |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't Date: 2011-02-24 |
Journal Detail:
|
Title: Stroke; a journal of cerebral circulation Volume: 42 ISSN: 1524-4628 ISO Abbreviation: Stroke Publication Date: 2011 Apr |
Date Detail:
|
Created Date: 2011-03-29 Completed Date: 2011-05-31 Revised Date: 2012-09-10 |
Medline Journal Info:
|
Nlm Unique ID: 0235266 Medline TA: Stroke Country: United States |
Other Details:
|
Languages: eng Pagination: 1135-7 Citation Subset: IM |
Affiliation:
|
Department of Radiology, University of Alberta, Edmonton, Alberta, Canada. |
| Data Bank Information | |
Bank Name/Acc. No.:
|
ClinicalTrials.gov/NCT01006993 |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Aorta, Abdominal / physiopathology Balloon Occlusion / adverse effects, instrumentation, methods* Cerebrovascular Circulation / drug effects, physiology* Combined Modality Therapy / instrumentation, methods* Female Fibrinolytic Agents / administration & dosage Humans Hypoxia-Ischemia, Brain / physiopathology, therapy* Infusions, Intravenous / methods Male Middle Aged Pilot Projects Thrombolytic Therapy / methods* Tissue Plasminogen Activator / administration & dosage |
| Grant Support | |
ID/Acronym/Agency:
|
//Canadian Institutes of Health Research |
| Chemical | |
Reg. No./Substance:
|
0/Fibrinolytic Agents; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Increased Thyroid Function and Elevated Thyroid Autoantibodies in Pediatric Patients With Moyamoya D...
Next Document: Disturbed Blood Flow Induces RelA Expression via c-Jun N-Terminal Kinase 1: A Novel Mode of NF-{kapp...